Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Author:

Michels Sebastian,Massutí Bartomeu,Schildhaus Hans-Ulrich,Franklin Jeremy,Sebastian Martin,Felip Enriqueta,Grohé Christian,Rodriguez-Abreu Delvys,Abdulla Diana S.Y.,Bischoff Helge,Brandts Christian,Carcereny Enric,Corral Jesús,Dingemans Anne-Marie C.,Pereira Eva,Fassunke Jana,Fischer Rieke N.,Gardizi Masyar,Heukamp Lukas,Insa Amelia,Kron Anna,Menon Roopika,Persigehl Thorsten,Reck Martin,Riedel Richard,Rothschild Sacha I.,Scheel Andreas H.,Scheffler Matthias,Schmalz Petra,Smit Egbert F.,Limburg Meike,Provencio Mariano,Karachaliou Niki,Merkelbach-Bruse Sabine,Hellmich Martin,Nogova Lucia,Büttner Reinhard,Rosell Rafael,Wolf Jürgen

Funder

Pfizer

Novartis

Roche

Boehringer Ingelheim

Eli Lilly

Project Management

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. A genomics-based classification of human lung tumors;Sci Transl Med,2013

2. RET, ROS1 and ALK fusions in lung cancer;Takeuchi;Nat Med,2012

3. Molecular pathways: ROS1 fusion proteins in cancer;Davies;Clin Cancer Res,2013

4. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer;Davies;Clin Cancer Res,2012

5. Recent advances in targeting ROS1 in lung cancer;Lin;J Thorac Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3